Anzeige
❌
Mehr »
Samstag, 21.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
EM

WKN: A2QD66 | ISIN: KYG3224E1061 | Ticker: 6HN
Tradegate
20.11.26 | 08:13
2,400 Euro
-3,23 % -0,080
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
EVEREST MEDICINES LTD Chart 1 Jahr
5-Tage-Chart
EVEREST MEDICINES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
2,4002,62013:04
2,4002,56020.11.

Aktuelle News zur EVEREST MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoEVEREST MED (01952): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 16 NOVEMBER 20262
MoEVEREST MED (01952): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE INCLUSION OF VELSIPITY AND XERAVA IN 2026 NATIONAL REIMBURSEMENT DRUG LIST1
13.11.EVEREST MED (01952): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE NEW 100 MG STRENGTH OF XERAVA APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ...1
30.10.EVEREST MED (01952): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - VIRTUAL MEETING ARRANGEMENTS FOR THE EXTRAORDINARY GENERAL MEETING-
30.10.EVEREST MED (01952): THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT1
30.10.EVEREST MED (01952): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, 16 NOVEMBER 20263
EVEREST MEDICINES Aktie jetzt für 0€ handeln
30.10.EVEREST MED (01952): NOTICE OF EXTRAORDINARY GENERAL MEETING3
30.10.EVEREST MED (01952): (1) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT; AND (2) NOTICE OF EXTRAORDINARY ...1
28.10.EVEREST MED (01952): BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING1
09.10.Everest Medicines Appoints Two to Strengthen Global mRNA R&D Capabilities2
09.10.Everest Medicines Limited: Two Former Moderna Cancer Vaccine Scientists Join Everest Medicines, Accelerating Global Development of Its mRNA Platform947HONG KONG, Oct 9, 2026 - (ACN Newswire) - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder...
► Artikel lesen
09.10.Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development319Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational...
► Artikel lesen
02.10.Everest Medicines Limited: Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial Momentum939HONG KONG, Oct 2, 2026 - (ACN Newswire) - Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the application...
► Artikel lesen
28.09.EVEREST MED (01952): TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE1
28.09.EVEREST MED (01952): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
28.09.EVEREST MED (01952): ESTABLISHMENT OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE1
28.09.EVEREST MED (01952): NEXT DAY DISCLOSURE RETURN-
21.09.Everest Medicines Limited: ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment Option550HONG KONG, Sept 21, 2026 - (ACN Newswire) - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients' daily lives...
► Artikel lesen
09.09.EVEREST MED (01952): CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT1
03.09.Everest Medicines Limited: Everest Medicines Strengthens Its Cardiovascular Portfolio with CARDAMYST(R) Approved for the Conversion of Acute Symptomatic Episodes of PSVT to Sinus Rhythm in Adults in China486HONG KONG, Sept 3, 2026 - (ACN Newswire) - Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of...
► Artikel lesen
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1